Perceptive Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Perceptive Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000,000	Closed	-$3.68M	–	138
2018 Q3	$3.68M	Hold	1,000,000	–	–	0.1%	76
2018 Q2	$2.83M	Hold	1,000,000	–	–	0.07%	85
2018 Q1	$3.71M	Hold	1,000,000	–	–	0.1%	83
2017 Q4	$2.88M	Buy	+1,000,000	New	+$3.63M	0.1%	84
2016 Q4	–	Sell	-929,290	Closed	-$7.53M	–	230
2016 Q3	$7.53M	Buy	+929,290	New	+$7.9M	0.49%	51
2015 Q1	–	Sell	-106,100	Closed	-$1.3M	–	188
2014 Q4	$1.3M	Sell	106,100 -63,900	-38%	-$780K	0.11%	97
2014 Q3	$1.7M	Sell	170,000 -110,000	-39%	-$1.02M	0.17%	77
2014 Q2	$2.12M	Buy	+280,000	New	+$1.12M	0.21%	64

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Perceptive Advisors's ACHN Position: Q4 2018 in Review

Perceptive Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 1,000,000 shares — an estimated $3.68M sold.

Perceptive Advisors first reported a position in ACHN in Q2 2014 and held it in 8 quarters. The position peaked at $7.53M in Q3 2016. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

Perceptive Advisors reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Perceptive Advisors sold 1,000,000 Achillion Pharmaceuticals shares in Q4 2018, an estimated $3.68M.
Perceptive Advisors first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Perceptive Advisors's Achillion Pharmaceuticals position peaked at $7.53M in Q3 2016.
121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.